Overview of the 2021 Chronic Hepatitis B Virus Infections Pipeline – With Arbutus Biopharma, Enyo Pharma and Gilead Sciences, among others – ResearchAndMarkets.com

0

DUBLIN – (COMMERCIAL THREAD) – The clinical trials “Chronic Hepatitis B Virus Infection – Pipeline Insight, 2021” have been added to ResearchAndMarkets.com offer.

This report provides comprehensive information on more than 45 companies and more than 45 pipeline drugs in the chronic hepatitis B virus infection pipeline landscape. It covers drug profiles in the pipeline, including clinical and non-clinical stage products. It also covers therapeutic evaluation by type of product, stage, route of administration and type of molecule. It further highlights inactive pipeline products in this space.

Chronic hepatitis B virus infection is a global public health threat resulting in significant liver-related morbidity and mortality. It is acquired at birth or later by person-to-person transmission. Vaccination effectively prevents infection and chronic carriage of the hepatitis B virus. In chronically infected patients, a high serum concentration of hepatitis B virus DNA is the main risk factor for disease progression. , although there are other clinical and viral parameters that influence the outcome of the disease. In addition to liver biochemistry, virologic markers, and abdominal ultrasound, the non-invasive assessment of hepatic fibrosis is emerging as an important assessment modality. Long-term nucleos

Chronic Hepatitis B Virus Infection – Pipeline Insight, 2021, the editor’s report presents comprehensive information on the current scenario and growth prospects across the indication. A detailed landscape picture of the Chronic Hepatitis B virus infection pipeline is provided, which includes disease overview and treatment guidelines for Chronic Hepatitis B virus infection. The evaluation portion of the report includes an in-depth commercial evaluation of chronic hepatitis B virus infection and clinical evaluation of pipeline products under development. In the report, a detailed description of the drug is given, which includes the mechanism of action of the drug, clinical studies, NDA approvals (if applicable) and product development activities including the technology, collaborations on the chronic hepatitis B virus infection, licensing, mergers and acquisitions. , financing, designations and other details related to the product.

Highlights of the report

Businesses and academics are working to assess challenges and research opportunities that could influence R&D on chronic hepatitis B virus infection. Therapies under development focus on new approaches to treat / ameliorate chronic hepatitis B virus infection.

Chapters on emerging drugs for chronic hepatitis B virus infection

This segment of the Chronic Hepatitis B Virus Infection report contains its detailed analysis of various drugs at different stages of clinical development including Phase II, I, Preclinical, and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, as well as the latest news and press releases.

Chronic hepatitis B virus infection Emerging drugs

AB-729 (GalNAc-ARNi): Arbutus Biopharma

AB-729 is a subcutaneous RNAi therapy targeting hepatocytes that inhibits viral replication and reduces all HBV antigens using our new covalently conjugated GalNAc delivery technology. Currently, it is in phase II development to treat chronic hepatitis B virus infection.

VIR-2218: Vir Biotechnology

VIR-2218, a siRNA targeting HBV, is designed to inhibit the production of all HBV proteins, including hepatitis B virus surface antigen (HBsAg), which in turn is believed to suppress l inhibition of the activity of T lymphocytes directed against HBV. We believe that it is possible to achieve functional cure for many HBV patients using VIR-2218 in combination with other agents. Currently, it is in phase II development to treat chronic hepatitis B virus infection.

Answers to key questions

Current treatment scenario and emerging therapies:

  • How many companies are developing drugs for chronic hepatitis B virus infection?

  • How many drugs for chronic hepatitis B virus infection are developed by each company?

  • How many emerging drugs are in the middle and advanced stages of development for the treatment of chronic hepatitis B virus infection?

  • What are the key collaborations (industry-industry, industry-university), mergers and acquisitions, licensing activities related to treatments for chronic hepatitis B virus infection?

  • What are the recent trends, types of drugs and new technologies being developed to overcome the limitations of existing therapies?

  • What are the ongoing clinical studies for chronic hepatitis B virus infection and their status?

  • What are the key designations that have been given to emerging drugs?

Key players

  • Arbutus Biopharma

  • Vir Biotechnology

  • Ascentage Pharma Group inc.

  • Biosciences Assembly

  • Nucorion Pharmaceuticals, Inc.

  • Hoffmann-La Roche

  • Enyo Pharma

  • Qilu Pharmaceutical Co., Ltd.

  • Ascletis Pharmaceuticals Co., Ltd.

  • Xiamen Amoytop Biotech

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

  • Romark LC Laboratories

  • Alios Biopharma inc.

  • Antios Therapeutics, Inc

  • Jiangsu HengRui Medicine Co., Ltd.

  • Enanta Pharmaceuticals

  • Janssen Pharma

  • Gilead Sciences

  • Replicor Inc.

  • Golden biotechnology company

  • Hepatera Ltd.

  • PharmaEssentia

  • Chong Kun Dang Pharmaceutical

  • Green Cross Society

  • Aligos Therapeutics

  • Sunshine Lake Pharma Co., Ltd.

  • Transgene

  • Tasly Tianjin Biopharmaceutical Co., Ltd.

  • GlaxoSmithKline

  • Henlix, Inc

  • Ionis Pharmaceuticals, Inc.

  • Altimmune, Inc.

  • Shanghai HEP Pharmaceutical

  • Dong-A ST Co., Ltd.

  • Enyo Pharma

  • CHA Vaccine Institute Co., Ltd.

  • Dicerna Pharmaceuticals, Inc.

  • Vaccitech (UK) Limited

  • Fujian Cosunter Pharmaceutical Co. Ltd

  • Regeneron Pharmaceuticals

  • VenatoRx Pharmaceuticals

  • ISA Pharmaceutical

  • Finch Therapeutic Group, Inc

  • Zhimeng Biopharma

  • VBI Vaccines Inc

  • GlobeImmune

For more information on this clinical trials report, visit https://www.researchandmarkets.com/r/rk0z4i

Leave A Reply

Your email address will not be published.